Seenu Hariprasad, MD
Shui-Chin Lee Professor of Ophthalmology and Visual
Science: Chief, Vitreoretinal Service: Director, Clinical
Research: Director, Fellowship in Vitreoretinal Diseases
and Surgery: The University of Chicago Medicine &
Michael Singer, MD
Medical Center Ophthalmology Associates
San Antonio, TX
Tom Albini, MD
Bascom Palmer Eye Institute
Dr. Seenu Hariprasad has disclosed that he is a consultant for Allergan, Novartis, EyePoint Pharmaceuticals and Alimera Sciences. He is on the Speaker’s Bureau for Allergan, Novartis, Alimera Sciences, EyePoint Pharmaceuticals, Spark Therapeutics and Regeneron Pharmaceuticals.
Dr. Michael Singer has disclosed that he receives grant/research support from Allergan, Aerie, Genentech, Regeneron, Eyepoint, Optos, Kodiak and Senju. He is a consultant for Allergan, Aerie, EyePoint Pharmaceuticals, Genentech, Regenreon. Dr. Singer serves on the Speaker’s Bureau for Allergan, EyePoint Pharmaceuticals, Genentech, Regeneron, and Spark Therapeutics and is a Stock Shareholder in Nancoscope and Inflammasome.
Dr. Tom Albini has disclosed that he is a consultant for Allegro Opthalmiocs, Allergan, Beaver, Visitec, Adverum Biotechnologies, EyePoint Pharmaceuticals, Novartis, Santen Pharmaceuticals, Genentech, Valeant Pharmaceuticals, Notal Vision, Janssen Biotech, Regenex Bio and Clearside Biomedical.
No one else in a position to control content has any relationships to disclose.
Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/.
Release Date: January 1, 2021
Expiration Date: December 31, 2021
Target Audience: This educational activity is intended for ophthalmologists and ophthalmologists in residency or fellowship training.
Upon completion of this activity, participants will be able to:
- Define the screening, examination, laboratory analysis and imaging processes that drive accurate and detailed uveitis diagnoses.
- Analyze the range of available and emerging treatment options for noninfectious and posterior noninfectious uveitis.
- Explain how to make the best match of treatment and patient to decrease patient burden while optimizing treatment outcomes.
- Review practice guidelines and options for adjustment in cases where treatment is intolerable or ineffective.
- Use the knowledge of recent pivotal clinical trial outcomes by comparing and differentiating three critical technologies to manage posterior segment noninfectious uveitis: Ozurdex, Yutiq, and the CLS-TA injection. Phase 3 clinical trial data will be reviewed to close the educational gap.
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Candeo Clinical/Science Communications, LLC. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resource for further study: https://jamanetwork.com/journals/jamaophthalmology/article-abstract/427281